Russia is not world’s first to develop Covid vaccine, says Kiran Mazumdar-Shaw


Kiran Mazumdar Shaw | Facebook


Text Size:

Bengaluru: Biotechnology industry veteran Kiran Mazumdar-Shaw has questioned Russian claims of developing the world’s first safe coronavirus vaccine, citing absence of data on clinical trials and “more advanced” programmes elsewhere.

The world has not seen any data on Phase 1 or 2 clinical trials conducted by Moscow-based Gamaleya Research Institute, the Executive Chairperson of Bengaluru-headquartered Biocon Ltd said.

“If launching a vaccine prior to completion of Phase 3 trials is acceptable to Russia, well so be it,” Mazumdar-Shaw told PTI.

“But it doesn’t make them the world’s first vaccine as several other vaccine programmes are even more advanced,” she added.

Russia announced on Tuesday it had become the first country to grant regulatory approval to a COVID-19 vaccine.

The first dose of the vaccine-Sputnik-V, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry, was administered to Russian President Vladimir Putin’s daughter.

Kiran Mazumdar-Shaw is among the distinguished founder-investors of ThePrint. Please click here for details on investors.


Also read: Russia’s Sputnik vaccine gamble is all about Vladimir Putin


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism